Apricus (APRI) Revisits MycoVa Strategy Following Recent Phase III Data

1311325429 47 Apricus (APRI) Revisits MycoVa Strategy Following Recent Phase III DataJune 27, 2011 10:19 AM EDT

Apricus Biosciences, Inc. (Nasdaq: APRI), reports that based on a successful and statistically significant reanalysis of its U.S. Phase III trials for its MycoVa product, originally intended for treating onychomycosis (nail fungus), it is revisiting its regulatory strategy for the drug. Specifically, a combined post-hoc analysis of two randomized, double-blind, vehicle controlled, multicenter, parallel group Phase III studies to assess the efficacy, safety and tolerability of MycoVa, demonstrated statistically significant results in mycological cure, resulting in the eradication of nail fungus in favor of active treatment in patients who did not present with comorbid tinea pedis (athlete’s foot), as these patients are considered at higher risk of reinfection.Are you missing key trading opportunities? Upgrade to StreetInsider Premium and get a step ahead of the market – FREE TRIAL!

Create E-mail AlertRelated Categories Corporate News FDA Stocks Mentioned

Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds – and more!

<a href="http://www.streetinsider.com/Corporate+News/Apricus+(APRI)+Revisits+MycoVa+Strategy+Following+Recent+Phase+III+Data/6603480.htmltag:news.google.com,2005:cluster=http://www.streetinsider.com/Corporate News/Apricus (APRI) Revisits MycoVa Strategy Following Recent Phase III Data/6603480.htmlMon, 27 Jun 2011 14:21:53 GMT 00:00″>Apricus (APRI) Revisits MycoVa Strategy Following Recent Phase III Data

Recommended Reading